Today on Drug Discovery & Development
Recent study finds Pfizer vaccine effective against Delta variant
The BNT162b2 COVID-19 vaccine from Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) leads to a strong neutralizing antibody response to the B.1.617 variant, according to a recent study published in Nature. The study focused on the B.1.617.2 subtype of the virus. Two others exist, known as B.1.617.1 and B.1.617.3. The study did acknowledge that the antibody…
Daiichi Sankyo’s valemetostat fares well in lymphoma and leukemia study
Valemetostat, a potential first-in-class drug from Daiichi Sankyo, led to durable tumor response in patients with peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL) in a Phase 1 study. The company presented highlights from the trial at the European Hematology Association (EHA) 2021 Virtual Congress today. In the study, the objective response rate was…
Drug Discovery and Development See More >
FDA advisory committee member reportedly resigns over Alzheimer’s therapy approval
A member of the FDA’s expert panel for nervous system therapies reportedly resigned over the decision to authorize an Alzheimer’s therapy. The FDA controversially authorized Aduhelm (aducanumab) from Biogen on Monday, making it the first novel Alzheimer’s drug treatment in 18 years despite drug companies pumping billions of dollars into more than 400 clinical trials. STAT…
Sponsored Content See More >
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
Unraveling the promise of genetics for treating progressive illness
For almost every major common disease, researchers have less understanding of the severe forms than milder cases. And as a result, people with severe forms of diseases often have few treatment options available. Thus, the significant unmet medical need for many diseases ranging from multiple sclerosis to Alzheimer’s is to halt disease progression and treat severe…
Vertex Pharmaceuticals wins FDA fast track designation for its cell-based diabetes treatment
How to build a foundation for the next phase of Alzheimer’s disease research
Why Genuity and Emory are partnering on neurodegenerative disease research
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Infectious Disease See More >
Pfizer’s Prevnar 20 vaccine wins FDA approval
Pfizer’s (NSE:PFE) pneumococcal 13-valent conjugate vaccine Prevnar 13 is one of pharma’s bestsellers, earning nearly $6 billion last year. Now, the company has scored FDA approval for its Prevnar 20 vaccine for adults 18 and older. The vaccine is the first to offer protection against 20 serotypes of pneumococcal disease that cause the majority of pneumonia and…
Oncology See More >
Daiichi Sankyo’s valemetostat fares well in lymphoma and leukemia study
Valemetostat, a potential first-in-class drug from Daiichi Sankyo, led to durable tumor response in patients with peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL) in a Phase 1 study. The company presented highlights from the trial at the European Hematology Association (EHA) 2021 Virtual Congress today. In the study, the objective response rate was…
